Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Short Interest Update

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 327,918 shares, a decrease of 25.8% from the December 15th total of 441,789 shares. Based on an average daily volume of 369,039 shares, the short-interest ratio is currently 0.9 days. Currently, 2.2% of the company’s shares are short sold. Currently, 2.2% of the company’s shares are short sold. Based on an average daily volume of 369,039 shares, the short-interest ratio is currently 0.9 days.

Insider Buying and Selling at Adagio Medical

In other Adagio Medical news, CEO Todd Usen acquired 207,315 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average cost of $1.09 per share, with a total value of $225,973.35. Following the transaction, the chief executive officer owned 207,315 shares of the company’s stock, valued at $225,973.35. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Adagio Medical

Large investors have recently made changes to their positions in the company. Cresset Asset Management LLC purchased a new position in Adagio Medical in the second quarter worth approximately $39,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of Adagio Medical by 17.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 821,261 shares of the company’s stock valued at $1,068,000 after purchasing an additional 121,261 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its position in shares of Adagio Medical by 0.7% during the 2nd quarter. Perceptive Advisors LLC now owns 9,876,576 shares of the company’s stock worth $12,840,000 after purchasing an additional 64,157 shares during the last quarter. 48.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADGM has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adagio Medical in a research note on Monday, December 22nd. Lake Street Capital began coverage on shares of Adagio Medical in a report on Tuesday, December 2nd. They issued a “buy” rating and a $4.00 price objective on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Adagio Medical currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Adagio Medical Stock Down 2.1%

Adagio Medical stock opened at $0.91 on Friday. The firm has a market capitalization of $14.00 million, a P/E ratio of -0.60 and a beta of 0.13. The company has a current ratio of 0.84, a quick ratio of 0.68 and a debt-to-equity ratio of 1.96. Adagio Medical has a twelve month low of $0.63 and a twelve month high of $2.87. The stock’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $1.33.

Adagio Medical (NASDAQ:ADGM) last released its earnings results on Thursday, October 30th. The company reported ($0.66) EPS for the quarter.

About Adagio Medical

Adagio Medical, Inc (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial.